Stem Cell Therapy Offers Promise to Reduce Symptoms of Chronic Pulmonary Disease

A recently released study appears to validate stem cell therapies as a viable and promising option for individuals diagnosed with serious pulmonary conditions such as chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, pulmonary fibrosis and interstitial lung disease. The study results were presented at the European Respiratory Society’s Lung Science Conference in Portugal and research revealed laboratory mice showed a marked reduction in pulmonary inflammation after the intravenous introduction of stem cells.

The Lung Institute has been ahead of the curve on using stem cell treatments for people diagnosed with chronic lung conditions and faced with limited clinical options. To date, over 4000 patients have undergone its autologous stem cell procedures and 84.5% report an improvement in their quality of life. Jack Coleman, Jr., M.D., Medical Director for the Lung Institute maintained recently “stem cell technologies are reshaping how medicine is practiced…

The autologous stem cell procedure used at The Lung Institute involves using adult stem cells taken from the affected individual’s own body, then reintroducing them intravenously, where the body’s own circulatory process rapidly sends them to the lungs, where the stem cells fight the inflammatory process which reduces lung capacity in chronic pulmonary disease. Although stem cells are most densely located in bone marrow, a less invasive venous procedure can be used on appropriate patients, repots The venous collection process requires no anesthetic and in many cases can provide an adequate supply of stem cells for therapeutic benefit.

Although treatment plans vary depending on the nature and extent of each individual patient’s progression of pulmonary disease, stem cell therapies provide an exciting promise for patients and their families. Watch videos about stem cell treatment on the Lung Institute’s YouTube channel.